ADAP woes deepen as budgets worsen and longevity improves. Could see capped enrollment, smaller formularies.
Ever since the AIDS Drugs Assistance Program (ADAP) faced the challenge of funding highly active antiretroviral treatment in the late 1990s, there have been annual funding problems--resulting in states taking actions to restrict drug formularies and cap enrollments. However, ADAP officials are seeing even more problems in FY 2003 due to Medicaid cuts and flag program funding.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics*; D002017:Budgets; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D008136:Longevity; D008483:Medical Assistance / Q000191:economics* / Q000458:organization & administration; D016019:Survival Analysis